Pre-Operative fSRS for Brain Metastases
Improving Outcomes in Patients With Metastatic Cancer to the Brain With Pre-Operative Fractionated Radiosurgery (fSRS): A Pilot Study
This pilot study investigates a new approach for patients with metastatic cancer that has spread to the brain (brain metastases) who are already planned to receive both fractionated stereotactic radiosurgery (fSRS) and brain surgery as standard treatment for their condition. Usually, surgery comes first, followed by radiation. However, post-operative radiation can sometimes lead to the cancer returning in the area, spreading to the brain's lining (LMD), or causing side effects from radiation (RN). This study hypothesizes that delivering fSRS before surgery may improve outcomes by enabling more accurate targeting, reducing tumor spillage, and potentially decreasing RN, while improving treatment compliance. The study is specifically testing the sequence of these two standard treatments.
This is a single-arm, prospective study enrolling 12 adult participants (age >18) with 1-5 brain metastases, where one main tumor (between 2.0-5.0 cm diameter) requires surgical resection. Participants will receive fSRS (27 Gy in 3 fractions) approximately one week prior to surgery, as part of the study's approach. Throughout the study, participants will also have regular brain MRI scans to monitor their condition and complete tests to check memory and thinking skills (like the MoCA test) at various points.
The main goal is to see how well the cancer is controlled at the surgery site (called local freedom from progression, or FFP) over 6, 12, 18, and 24 months post-operatively. Secondary outcomes include rates of LMD and RN. Safety (adverse events, toxicities) will be continuously monitored by an independent Data Safety Monitoring Committee (DSMC). Each participant will be in the study for 2 years.
This research aims to provide preliminary data to inform future larger, randomized trials, ultimately improving treatment strategies for patients with metastatic brain cancer.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
New York
-
New York、New York、アメリカ、10075
- Lenox Hill Hospital, Northwell Health
-
主任研究者:
- A. Gabriella Wernicke, MD, MS
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patient is ≥18 years old.
- Radiographic confirmation of 1-5 brain metastases by MRI with contrast obtained within 4 weeks prior to registration. One of these must be an index lesion requiring surgical resection.
- The maximum diameter of the index lesion, as measured on any orthogonal plane (axial, sagittal, coronal) on the post-contrast MRI, must be ≥2.0 cm and ≤5.0 cm.
- Documented pathological diagnosis of active or history of invasive cancer within the past 5 years.
- All brain metastases must be located ≥5 mm from the optic chiasm and outside the brainstem.
- Patient can medically tolerate surgery and fSRS. The treating surgeon must deem the index lesion an appropriate target for safe resection.
- Karnofsky Performance Status (KPS) ≥50 within 14 days prior to registration.
- A negative urine or serum pregnancy test (for individuals of childbearing potential) ≤14 days prior to registration.
- Patient or legally authorized representative provides study-specific informed consent before study entry. For patients treated in the U.S., authorization permitting release of personal health information is also required.
Exclusion Criteria:
- Previous cranial radiotherapy, including whole-brain radiotherapy or stereotactic radiosurgery (SRS), to the planned resection site (index lesion). Repeat radiosurgery to the same location/lesion is not permitted on this protocol.
Note: Prior or current fSRS/SRS to other non-index lesions is allowed.
- Evidence of leptomeningeal disease.
- Any contraindication or inability to undergo MRI with contrast.
- Planned administration of cytotoxic chemotherapy or tyrosine/multi-kinase inhibitors within 3 days prior to, on the day of, or within 3 days after the completion of fSRS.
Note: Chemotherapy and immunotherapy outside of this window are allowed.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Pre-Operative fSRS Followed by Re-Section
This arm consists of all enrolled participants who will receive fractionated stereotactic radiosurgery (fSRS) prior to neurosurgical resection of their brain metastasis. This approach investigates a modified sequence of two standard-of-care treatments for this condition, aiming to evaluate its safety and efficacy. |
Pre-operative fSRS to a dose of 27 Gy in 3 fractions will be delivered to the index lesion every other day. These radiation treatments will be completed within 1 week (+/- 5 days) prior to surgical resection. This is a standard radiation procedure for brain metastases. Surgical removal of the brain metastasis (index lesion) performed after completion of pre-operative fSRS. This is a standard surgical procedure for brain metastases.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Local Freedom from Progression (FFP) within the Resection Cavity
時間枠:6, 12, 18, and 24 Months Post-Operative
|
The absence of new nodular contrast enhancement 2 mm or less from the resection cavity. |
6, 12, 18, and 24 Months Post-Operative
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Leptomeningeal Disease (LMD)
時間枠:From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years
|
Documented incidence of LMD on brain MRI imaging |
From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years
|
|
Incidence of Radiation Necrosis (RN)
時間枠:From post-operative (48-72 hours after surgery) through every 3 months for 2 years
|
Documented incidence of RN on brain MRI imaging |
From post-operative (48-72 hours after surgery) through every 3 months for 2 years
|
|
Change in Neurocognitive Function
時間枠:Baseline, Post-Operative Visit, and Every 3 Months for 2 Years
|
Assessed using the Montreal Cognitive Assessment (MoCA) score |
Baseline, Post-Operative Visit, and Every 3 Months for 2 Years
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Correlation of Pathologic Information Between Primary Cancer and Resected Brain Metastasis
時間枠:Between Surgery and Post-Operative Visit
|
Comparison of pathological characteristics of resected brain metastasis with the primary tumor |
Between Surgery and Post-Operative Visit
|
|
Correlation of Extent of Surgical Resection with Survival Outcomes
時間枠:From study registration until 2 years post-operative or death
|
Evaluation of the Association between extent of surgical resection and Progression-Free Survival (PFS) and Overall Survival (OS) |
From study registration until 2 years post-operative or death
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Shepard MJ, Sheehan JP. The Choice of Postoperative Stereotactic Radiosurgery After Resection of an Isolated Brain Metastasis. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):940. doi: 10.1016/j.ijrobp.2018.05.081. Epub 2019 Oct 24. No abstract available.
- Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1040-1048. doi: 10.1016/S1470-2045(17)30414-X. Epub 2017 Jul 4.
- Palmer JD, Perlow HK, Matsui JK, Ho C, Prasad RN, Liu K, Upadhyay R, Klamer B, Wang J, Damante M, Ghose J, Blakaj DM, Beyer S, Grecula J, Arnett A, Thomas E, Chakravarti A, Lonser R, Hardesty D, Prevedello D, Prabhu R, Elder JB, Raval RR. Fractionated pre-operative stereotactic radiotherapy for patients with brain metastases: a multi-institutional analysis. J Neurooncol. 2022 Sep;159(2):389-395. doi: 10.1007/s11060-022-04073-w. Epub 2022 Jun 25.
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 26-0403
- 23-004 (その他の識別子:Northwell Health Cancer Institute)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
A formal plan for sharing individual participant data (IPD) has not been developed or approved for this pilot study. Participant confidentiality and privacy are strictly maintained, and study data will be transmitted and stored internally at the Northwell Health Cancer Institute (NHCI) in a de-identified format for statistical analysis and scientific reporting. Results will be disseminated through publications that do not contain identifying information.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。